847926-81-2 Usage
Description
C-(2,2-Difluoro-cyclopropyl)-MethylaMine, also known as (2,2-Difluorocyclopropyl)methylamine, is a difluorinated-derivative of Cyclopropylmethylamine (C988695). It is a chemical compound that plays a significant role in the synthesis of various pharmaceutical agents.
Uses
Used in Pharmaceutical Industry:
C-(2,2-Difluoro-cyclopropyl)-MethylaMine is used as a reagent in the synthesis of pyrrolidine derivatives. These pyrrolidine derivatives act as alternative pathway modulators and are utilized for the treatment of ophthalmic and other diseases. C-(2,2-Difluoro-cyclopropyl)-MethylaMine contributes to the development of innovative therapeutic agents that address unmet medical needs.
Used in Medicinal Chemistry Research:
C-(2,2-Difluoro-cyclopropyl)-MethylaMine also serves as the starting material in the synthesis of dihydrodiazepines. These dihydrodiazepines function as protein kinase inhibitors, playing a crucial role in the regulation of various cellular processes. C-(2,2-Difluoro-cyclopropyl)-MethylaMine is instrumental in advancing the discovery and development of potential therapeutic agents targeting protein kinases, which are implicated in numerous diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 847926-81-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,4,7,9,2 and 6 respectively; the second part has 2 digits, 8 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 847926-81:
(8*8)+(7*4)+(6*7)+(5*9)+(4*2)+(3*6)+(2*8)+(1*1)=222
222 % 10 = 2
So 847926-81-2 is a valid CAS Registry Number.
847926-81-2Relevant articles and documents
PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS
-
Page/Page column 86; 87, (2014/01/17)
The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as complement pathway modulators for the treatment of ocular diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
